News | Image Guided Radiation Therapy (IGRT) | July 16, 2019

AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy

Presentations highlight MRIdian clinical experience with real-time on-table adaptive radiotherapy at a growing number of institutions worldwide

AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy

July 16, 2019 — ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2019 Annual Meeting, July 14-18 in San Antonio, Texas.

Magnetic resonance imaging (MRI)-guided radiotherapy will be highlighted in a number of abstracts and posters throughout the scientific program at AAPM 2019, illustrating the growing interest in this treatment approach. The MRIdian-specific research being presented will cover topics including motion prediction, quality assurance, stereotactic body radiation therapy (SBRT), adaptive therapy and tumor response assessment. These abstracts feature MRIdian experience from institutions such as: 

  • Washington University School of Medicine in St. Louis; 
  • Henry Ford Health System (HFHS); 
  • University of California Los Angeles (UCLA); 
  • University of Wisconsin; 
  • Loyola University Medical Center, Chicago; 
  • University of Miami; 
  • Miami Cancer Institute at Baptist Health South Florida; 
  • Institute of Health Science at Acibadem University, Istanbul; 
  • Amsterdam University Medical Centers; 
  • The NewYork-Presbyterian Hospital; 
  • UF Health Cancer Center at Orlando Health; 
  • Institut Paoli-Calmettes, Marseille; 
  • Rigshospitalet Copenhagen; and 
  • Heidelberg University Hospital.

Noteworthy MRIdian abstracts featured in AAPM's Scientific Program include:

AAPM attendees can learn more about MRIdian and MRI-Guided Real-time On-table Adaptive Radiotherapy (ROAR) in ViewRay's booth. Presentations will be made in the company's booth throughout the meeting by MRIdian clinical users. Presenters will share their MRIdian experience and highlight topics such as the value of MRI-guided RT, real-time tracking and automated gating, optimal magnetic field strength for RT, adaptive therapy workflows, online quality assurance, program implementation and clinical efficiencies.

The ViewRay booth will also feature demonstrations of the MRIdian System's adaptive workflow, which helps to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses. 

For more information: www.viewray.com

Related Content

VIDEO: Walk Through of the MRI Radiotherapy System at Henry Ford Hospital

VIDEO: MRI-Guided Radiation Therapy Trial for Pancreatic Cancer

VIDEO: Clinical Use of the ViewRay MRIdian Linac System at Henry Ford

Related Content

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i
The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly

Image courtesy of GE Healthcare

News | Magnetic Resonance Imaging (MRI) | February 11, 2020
February 11, 2020 — The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly in the fo
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Qynapse, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore software
News | Information Technology | February 04, 2020
February 4, 2020 — Qynapse, a medical technology company, anno
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
RSNA 2019

RSNA 2019

Feature | Radiology Imaging | January 31, 2020 | By Greg Freiherr
The founder of Gonzo journalism thought